Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Superantigen antagonist peptides.

M Llewelyn1, J Cohen

  • 1Department of Infectious Diseases, Imperial College School of Medicine, Hammersmith Hospital, London, UK.

Critical Care (London, England)
|April 12, 2001
PubMed
Summary

Toxic shock syndrome is caused by bacterial superantigens. Blocking the interaction between superantigens, T cell receptors, and MHC class II molecules may offer future treatment for these diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AIDS vaccines: is older better?

Science (New York, N.Y.)·1992
Same author

AIDS vaccines. Trials set in high-risk populations.

Science (New York, N.Y.)·1992
Same author

Dingell rips Healy for 'obstructionism'.

Science (New York, N.Y.)·1992
Same author

Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release.

Lancet (London, England)·1992
Same author

Pediatric AIDS vaccine trials set.

Science (New York, N.Y.)·1992
Same author

A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies.

The Journal of antimicrobial chemotherapy·1992

Area of Science:

  • Microbiology
  • Immunology
  • Toxicology

Background:

  • Gram-positive bacteria produce superantigenic exotoxins, which are central to toxic shock syndrome (TSS) pathology.
  • TSS involves an excessive and disordered inflammatory response triggered by superantigens.

Purpose of the Study:

  • To review emerging treatment strategies for superantigen-mediated diseases.
  • To present the first published data on blocking the superantigen-TCR-MHC II interaction.

Main Methods:

  • Review of existing and experimental treatments for superantigen-mediated diseases.
  • Analysis of data targeting the three-way interaction between superantigen, T cell receptor (TCR), and major histocompatibility class II (MHC II) molecule.

Main Results:

  • The article introduces a novel therapeutic strategy focused on disrupting the superantigen-TCR-MHC II complex.
  • This approach aims to mitigate the hyperinflammatory response characteristic of TSS and related conditions.

Conclusions:

  • Blocking the superantigen-TCR-MHC II interaction represents a promising therapeutic avenue for superantigen-mediated diseases.
  • Further research and clinical evaluation are warranted for this strategy in the context of existing treatments.

Related Experiment Videos